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Apart from its principal role in bone metabolism and calcium homeostasis, vitamin D has been attributed additional
effects including an immunomodulatory, anti-inflammatory, and possibly even neuroprotective capacity which
implicates a possible role of vitamin D in autoimmune diseases like multiple sclerosis (MS). Indeed, several lines of
evidence including epidemiologic, preclinical, and clinical data suggest that reduced vitamin D levels and/or
dysregulation of vitamin D homeostasis is a risk factor for the development of multiple sclerosis on the one hand,
and that vitamin D serum levels are inversely associated with disease activity and progression on the other hand.
However, these data are not undisputable, and many questions regarding the preventive and therapeutic capacity
of vitamin D in multiple sclerosis remain to be answered. In particular, available clinical data derived from
interventional trials using vitamin D supplementation as a therapeutic approach in MS are inconclusive and partly
contradictory. In this review, we summarise and critically evaluate the existing data on the possible link between
vitamin D and multiple sclerosis in light of the crucial question whether optimization of vitamin D status may
impact the risk and/or the course of multiple sclerosis.
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Multiple sclerosis: background information
Multiple sclerosis (MS) is the most common chronic in-
flammatory disease of the central nervous system (CNS)
in young adults in Western countries and often leads to
early disability and retirement [1]. Typical clinical manifes-
tations are optic neuritis, central paralysis, sensory distur-
bances, and difficulties in coordination and balance, as
well as cognitive dysfunction, fatigue, and sleep disorders
[1-3]. The initial course is usually relapsing-remitting, but
after several years, the disease tends to convert into a sec-
ondary progressive form. A primary progressive course
also exists but is much less common. It is estimated that
2.5 million people suffer from MS worldwide, and as in
most autoimmune disorders, there is an obvious female
preponderance of approximately 3 to 4:1 [1,4]. Import-
antly, most female patients are affected in their child-* Correspondence: jan-markus.doerr@charite.de
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provided the original work is properly cited.bearing age which may have fundamental consequences
for family planning [5]. The cause of MS is not yet clear.
Several genetic and environmental factors have been iso-
lated to contribute to the risk of MS, among them vitamin
D (VD) status, but the individual significance of each fac-
tor is not yet clear [6-10]. From the pathophysiological
point of view, dysregulated encephalitogenic T cells are
thought to initiate and to orchestrate in concert with
abundant other immune cells an autoimmune multifocal
CNS inflammation [11-13]. For decades, MS was consid-
ered to be a primarily demyelinating disorder predomin-
antly affecting the CNS white matter. During recent years,
however, it has become clear that MS also has a strong
neurodegenerative component, which is most probably
the underlying basis for the development of permanent
disability [14-17]. Moreover, grey matter involvement has
been increasingly recognised by means of histopathology
and magnetic resonance imaging (MRI) [18-20]. Paraclin-
ical tools for diagnosis, differential diagnosis, and monitor-
ing of disease activity and progression in MS comprise
cerebrospinal fluid examination, evoked potentials, MRI,
and recently, optical coherence tomography [1,21-24].le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
Table 1 Dietary sources of vitamin D [37]
Food product Vitamin D content
(μg/100g)
Required daily intake
(in g) for 20 μg vitamin D
Cod liver oil 330 6
Smoked eel 22 91
Salmon 3.8 526
Avocado 3.43 583
Egg yolk 2.9 690
Liver (beef) 1.7 1,176
Butter 1.2 1,667
Pork 0.11 18,182
Milk (3.5%) 0.088 22,727
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immunomodulatory or immunosuppressive drugs such as
interferon-beta, glatiramer acetate, fingolimod, natalizu-
mab, or mitoxantrone [25,26]. Approval of additional new
drugs is expected. However, most if not all of these drugs
lack convincing neuroprotective capacity. Moreover, a
substantial number of patients do not respond satisfyingly
to these drugs or experience severe side effects [27-31].
Overall, there is still a need for improved therapeutic
approaches, especially in neuroprotective substances [32].
Vitamin D: background information
Research on VD started around 1915, stimulated by the
quest for an effective treatment of rickets. By the end of
the 19th century, up to 90% of the children living in large
cities throughout Northern Europe and the United States
suffered from rickets, and the most common cause was
the insufficient supply of VD due to low sun exposure as a
side effect of increasing industrialisation. The transfor-
mation to an industrialised economy radically changed the
living conditions for large parts of the population. Chil-
dren often had to work many hours a day in factories or
mines, being completely shielded from the sun. When VD
deficiency was recognised as the main cause of rickets, a
significant reduction of cases was achieved by preventive
measures like radiation from ultraviolet lamps, greater
amount of time spent outdoors, or fortification of food
with VD [33].
The VD supply of the human organism is generally
accomplished via two different routes: first, endogenous
synthesis of VD3 (cholecalciferol) from its precursor 7-
dehydrocholesterol in an ultraviolet (UV) B radiation-
dependent process in the skin (wave length 290 to 315 nm);
second, exogenous supply withVD3 or VD2 (ergocalciferol)
by food, fortified food products, or supplements [34,35].
About 90% to 100% of theVD requirement of a human body
is covered by sun exposure-dependent endogenous produc-
tion [33,36]. The amount of UVB-radiation dependent VD
production depends on numerous factors including indivi-
dual factors like duration and frequency of sun exposure,
the area of skin exposed to the sun, use of sun protection,
skin pigmentation, age, sex, genetic factors, amounts of 7-
dehydrocholesterol in the skin; geographic factors like lati-
tude and altitude; as well as seasonal and meteorological
factors like clouding and ozone levels [36]. The magnitude
of endogenous VD synthesis is referenced to the minimum
erythema dose (MED) which describes the minimum indi-
vidual dose of UVB radiation needed for the development
of a transient skin irritation. One MED of the entire body
equals the release of 10,000 to 20,000 IU (250 to 500 μg) of
VD3 [1]. Compared to the endogenous production of VD3,
the food-related intake of VD2/3 is usually of inferior im-
portance since only few food products contain significant
amounts of VD (Table 1).Both VD2 and VD3 are biologically inactive. After intra-
dermal synthesis or intestinal uptake, VD2 and VD3 are
bound mainly to vitamin-D-binding-protein and trans-
ported to the liver, where they are enzymatically hydroxy-
lated to 25(OH)VD (calcidiol). As this step is not tightly
regulated and because of the relatively long half-life, serum
levels of 25(OH)VD integrate both the endogenous and
exogenous supply and provide a good estimate of an orga-
nism's VD status. The enzyme 1α-hydroxylase (CYP27B1),
which is located mainly in the kidneys but also in other
tissues, converts 25(OH)VD in a second hydroxylation
step into the biologically active 1,25 dihydroxyvitamin D
(1,25(OH)2VD; calcitriol) [35]. Unlike the first hydroxyl-
ation, this second step is tightly regulated, among others
by parathormone and calcium/phosphate levels [38]. Cal-
citriol effects are mainly mediated via the intracellular VD
receptor (VDR) which functions as a transcription factor
and controls the expression of numerous genes. In its
membrane-bound form, VDR mediates additional non-
genomic functions including several signal transduction
pathways [39,40].
An ongoing debate addresses the optimal serum levels
of 25(OH)VD. Currently, most experts consider 25(OH)
VD levels above 30 ng/ml (75 nmol/l) as adequate [41-
43], which is supported by the observations that serum
levels of parathormone start plateauing at serum 25(OH)
VD of 30 to 40 ng/ml and that immunological effects
need serum levels around 30 ng/ml [35,44]. Levels below
20 ng/ml (50 nmol/l) are considered deficient. Less clear
are the upper limits since substantial variability occurs in
naturally occurring 25(OH)VD levels. According to the
literature, levels of up to 150 to 200 ng/ml (375 to 500
nmol/l) can be considered safe [41]. Against this back-
ground, a significant proportion of the human population
worldwide shows an alarming VD inadequacy [35,44-46].
Since VD homeostasis is linked on multiple levels to
the risk of not only various diseases such as cancer and
autoimmune diseases, but also metabolic, cardiovascular,
and psychiatric disorders [35,42,47,48], the question
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or even treat respective diseases. Indeed, recent estima-
tions indicate that yearly, >110,000 deaths could be pre-
vented by adequate VD supply [49].
Linking vitamin D and MS: immunoregulatory functions
of vitamin D
Apart from its fundamental role in calcium homeostasis
and bone metabolism, increasing evidence suggests that
VD has additional, particularly immunoregulatory func-
tions which renders VD a promising candidate in both
pathogenesis and treatment of autoimmune diseases such
as MS. The capability of VD to modulate both innate and
adaptive immune responses has been summarised in
several comprehensive and excellent reviews [47,50-52].
With respect to the autoimmune MS pathophysiology
[11,12], the following effects of VD on the immune system
might be of particular interest: the ability to modulate the
differentiation and function of antigen presenting cells
which results in a reduced activation of potentially auto-
aggressive T cells [53-55], the capacity to inhibit B cell and
T cell proliferation and differentiation [56-58], the ability
to shift the cytokine milieu from a pro-inflammatory, Th1/
Th17-cell-mediated to a rather anti-inflammatory Th2-
cell-mediated state [47,59], and finally, to facilitate the
differentiation of regulatory T cells and function of natural
killer cells [60,61]. Data on the VD effect on CD8 cells
are still controversial. Figure 1 summarises the potentialFigure 1 Possible effects of vitamin D on immune cells. APC, antigen p
plasma cell; NKC, natural killer cell. Figure was first published in [62].immunoregulatory effects of VD that might be patho-
physiologically relevant in MS.
The presence of 1α-hydroxylase activity in neurons and
microglia, and the presence of VD receptor in the CNS
suggest local-, paracrine-, or autocrine-mediated effects of
VD in the CNS [63,64]. Interestingly, data from in vitro or
animal studies suggest that neurotrophic factors such as
nerve growth factor, neurotrophin 3, and glial cell line-
derived neurotrophic factor are regulated by VD which
might indicate additional, possibly neuroprotective effects
of VD [65]. Whether VD has clinically relevant neuropro-
tective properties still remains a subject of discussion.
Linking vitamin D and MS: how do genes contribute?
It is long known that genetic factors contribute to the
risk of MS. In particular, an association with extended
major histocompatibility complex haplotypes, especially
those containing HLA-DRB1*1501, has been consistently
shown in individuals of northern European ancestry
[66,67]. The role of VD-related genes in determining MS
risk or specific genetic interactions with VD is currently
a hot focus of research and is not yet completely under-
stood. So far, two interesting links merit mentioning: First,
it was recently shown that the gene expression of allele
HLA-DRB1*1501 is modulated by VD, and a highly con-
served VD-responsive element has been identified in the
promoter region of the HLA-DRB1*1501 haplotype, which
may indicate a direct functional interaction between VDresenting cell; Th, T helper cell; Treg, regulatory T cell; BC, B cell; PC,
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MS [68]. Second, loss of function variants in the CYP27B1
gene which encodes the enzyme that converts 25(OH)VD
into its active form were shown to be associated with an
increased MS risk [69]. In the same direction points a pos-
sible association between MS and VD-dependent rickets
type I, which is a rare hereditary condition caused by a
mutation in CYP27B1 [70,71].
Linking vitamin D and MS: what do animal models tell us?
Further evidence for a causal relation between VD sup-
ply and both development and treatment of MS were
derived from experimental autoimmune encephalomyeli-
tis (EAE), the best established rodent animal model for
MS. In murine EAE, prophylactic application of VD
(starting at disease induction) resulted in a reduction of
both disease incidence and severity. Likewise, the thera-
peutic VD application (starting at onset of symptoms)
lead to a significant reduction of disease severity [72-74].
Interestingly, some studies suggested gender-specific ef-
ficacy of VD only in female mice [75]. In a recent study,
continuous treatment of mice with UVR dramatically
suppressed clinical signs of EAE. Interestingly, the thera-
peutic effect was paralleled by only a moderate and transi-
ent increase of serum 25(OH)VD levels, which suggests
that directly UVR-mediated effects which were at least
partly independent of VD contributed to this observation
[76]. In another recent study using the cuprizone model,
dietary VD could (partly) prevent chemically induced CNS
demyelination in mice [77].
Linking vitamin D and MS: the clue to geographic and
seasonal associations?
First hypotheses on a possible link between MS risk and
VD deficiency were derived from the observation that the
risk of MS is associated with latitude [78,79] which in turn
shows a strong inverse correlation with UVB exposure.
Furthermore, migrating from high to low latitude appears
to reduce the MS risk [80]. This link was further corrobo-
rated by the observation of a MS risk lower than one
would expect from the latitude in regions with a high con-
sume of fatty VD-rich fish [81]. More recent investiga-
tions, however, suggest that this latitude gradient is fading
which might be explained by several possible reasons, in-
cluding better MS recognition, changes in lifestyle, and
improvement of sanitary circumstances [34]. More indir-
ect though not unambiguous support for a beneficial effect
of VD comes from the observation that both MS risk and
disease activity show a seasonal association. As shown in
several studies including a very recent meta-analysis,
humans born in spring have a significant higher risk to de-
velop MS later in life than people born in autumn [82-85]
which might be at least partially explained by longer in
utero VD insufficiency due to lower motherly VD levels inwinter/spring as compared to summer/autumn. Likewise,
several methodically high quality studies showed an in-
verse association between sun exposure or outdoor activ-
ities during childhood and adolescence, and the risk of
developing MS during adulthood [86-90]. In line with
these reports is the recent observation that low sun expos-
ure in fall/winter before disease onset was associated with
a less favourable outcome [91]. Yet, all these studies have
two major intrinsic limitations: first, despite a reported
reasonable validity and reliability [92], the retrospective
determination of sun exposure years or even decades in
the past is inevitably subjected to recall bias [34], and pro-
spective studies are hardly available. The determination of
actinic damage as a surrogate parameter for cumulative
sun exposition might be a viable loophole [34,86]. Second,
sun exposure itself may have intrinsic immunomodulatory
effects, independent of VD [76,93,94]. Also, not easy to
harmonise with sun exposure or VD synthesis is the sea-
sonal dependency of disease activity in already established
MS. Several studies including a meta-analysis showed an
excess of clinical exacerbations and MRI activity in spring/
summer and a nadir in autumn/winter in the northern
hemisphere [95-98]. Correspondingly, a reverse situation
was observed in the southern hemisphere [99]. While a
peak of disease activity in spring and a nadir in autumn in
the northern hemisphere could be explained with a few-
month lag in the course of serum VD levels, the situation
in summer and winter does not easily fit with a protective
role of VD. In conclusion, VD might contribute to some
but cannot sufficiently explain all geographic and seasonal
associations observed in MS.
Linking vitamin D and MS: the impact of vitamin D intake
and serum level
The rather indirect impact of predictors of 25(OH)VD
levels on MS has been discussed above. But, how does the
25(OH)VD serum level itself sway the risk and course of
MS? Generally, if VD had a beneficial effect on MS risk,
one would demand an inverse relation between VD intake
or serum levels and MS incidence. Indeed, various studies
demonstrated such a relation. Most data on this issue,
however, are derived from epidemiologic or observational
studies, meaning, that methodical limitations like selection
bias, retrospective survey, and interference with various
confounders should be kept in mind. One recent study
suggests that already in utero levels of VD, which are com-
pletely dependent on the mother's VD status, impact the
risk to develop MS later in life [100]. In a Canadian cohort
study on children presenting with a first demyelinating
event, the risk to develop definite MS within the following
3 years was inversely and independently correlated with
the 25(OH)VD serum level [101]. Furthermore, data from
a nested case–control study involving more than seven
million individuals of the US military suggest that in
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predictive of a significantly lower risk of developing MS
(62% lower odds in the top quintile of 25(OH)VD serum
levels compared to the bottom quintile), independent
from latitude of residency in childhood [102]. Another
study by the same group addressed the relation between
VD intake and MS risk in a cohort of approximately
200,000 US women and reported a 33% reduction of MS
incidence over a follow-up period of 30 years when com-
paring the top quintile and the bottom quintile of VD in-
take. Moreover, in women taking daily supplements
containing at least 400 IU VD, a 41% lower MS incidence
was observed when compared to women who did not take
supplements [103]. Likewise, in another survey, intake of
cod liver oil was associated with a 4-year delay of MS onset
[90]. In summary, substantial evidence exists for an inverse
association between VD and the risk of developing MS.
But, how does the situation look in already established
MS? A number of studies consistently suggest that higher
VD serum levels are associated with a more favourable
disease course. In a small Finnish study, lower summer 25
(OH)VD concentrations were measured in patients with a
first MS relapse compared to healthy controls, and 25
(OH)VD concentrations were significantly lower during
relapses than in remission phases which may point to a
regulative role of VD for MS activity [104]. Compelling
support for this hypothesis comes from four independent
recent reports, all showing a close relationship between
clinical disease activity and 25(OH)VD concentrations:
Two studies demonstrated that every 10 nmol/l increase
of the VD serum level is correlated with a reduction of re-
lapse occurrence of 11% and 13.7%, respectively [105,106].
A third study demonstrated a log linear association be-
tween serum VD concentration and MS relapse rate in
that every doubling of serum levels reduced relapse rate
by 27% [107]. The fourth study finally revealed a 34% re-
duction of relapse rate by every 10 ng/ml increase in
paediatric onset MS [108]. In line with these clinical data,
an inverse association between VD concentrations and
disease activity on cranial MRI was recently demonstrated,
but may possibly be restricted to patients without add-
itional immunomodulatory treatment [109,110]. Of note,
in studies addressing the relation between clinical disease
activity and VD levels, a reverse association (low VD con-
centrations as a consequence rather than a cause of a
relapse) cannot be completely ruled out. In contrast to
the serum concentrations, a statistical difference in
cerebrospinal fluid VD levels was neither observed be-
tween MS patients and healthy controls or in MS
patients between phases of disease activity or in remis-
sion [111].
In conclusion, cumulating evidence quite consistently
argues for a relationship between VD status and both
risk and activity of MS. Of note, however, all thesestudies are methodically prone to bias and are therefore
not suited to definitely proof such a relation.
Linking vitamin D and MS: what do interventional trials
tell us?
The compelling evidence for the beneficial impact of
higher VD serum concentrations on disease activity leads
directly to two questions: (a) do patients with already
established MS benefit from a therapeutic elevation of
their VD levels and (b) if so, which 25(OH)VD serum
levels should be strived for in MS patients? To reliably an-
swer these crucial questions, high quality and sufficiently
powered interventional trials are required. Moreover, im-
portant issues like optimal dosing schemes need further
clarification. So far, there are only few prospective clinical
studies on VD as a treatment for MS, some of them of
rather questionable quality. An early uncontrolled study
involving 16 MS patients (evidence level IIb) showed that
regular intake of cod liver oil (equivalent to 5,000 IU VD/
day) for a period of up to 2 years lead to a lower relapse
rate as would have been expected from the participants'
medical histories [112]. From today's point of view, design
and sample size of this study are however not appropriate
to address a therapeutic effect of VD. Another small and
uncontrolled study with a primary focus on safety aspects
(evidence level IIb) provided evidence that escalating VD
doses up to 280,000 IU/week over a rather short period of
28 weeks are safe in MS patients. No significant effects on
clinical parameters were observed, but there was a pos-
sible effect on MRI activity [113]. In a successive rando-
mised controlled but open label study, the same group
applied cholecalciferol (up to 40,000 or 4,000 IU/d) con-
tinuously for 52 weeks in 49 MS patients (evidence level
Ib). Patients in the high dose arm showed a significant
reduction of the annualised relapse rate [114]. In another
randomised double blind and placebo-controlled study
focusing on serological markers of disease activity (evi-
dence level IIb), administration of 1,000 IE cholecalciferol
for a period of 6 months lead to a significant increase of
the anti-inflammatory cytokine transforming growth
factor-β and to a partial reduction of the IL-2 level [115].
Another recent study (evidence level IIb) reported no
significant differences between the high- or low-dose ergo-
calciferol on clinical and MRI parameters [116]. However,
the design of this study (small number, inhomogeneous
group of patients, short period of observation, relatively
high dosages of “low-dose” ergocalciferol) has been criti-
cised as not being suited to address the therapeutic cap-
acity of VD in MS [117]. The capacity of low dose
calcitriol to prevent disease progression in relapsing remit-
ting multiple sclerosis (RRMS) when given in adjunction
to undefined disease-modifying treatment strategies was
investigated in a randomised and double blind but rather
small study on 50 patients. After 12 months, no significant
Table 2 Ongoing clinical trials on vitamin D in multiple sclerosis (registered at www.clinicaltrials.gov by January 2013)
Trial title/registration number Sponsor Start date/estimated
completion date
Intervention Trial design Number of
participants
Main outcome parameters
Phase II study of efficacy of
vitamin D supplementation in
multiple sclerosis (EVIDIMS study)
Charité-
Universitätsmedizin
Berlin, Germany
December 2011/
March 2015
Cholecalciferol 20,400 IU
every other day (high
dose) or cholecalciferol
400 IU/every other day
(low dose) for 18 months
Randomised double
blind active controlled
multicenter Phase II
trial
80 patients with
RRMS or CIS
Primary: cumulative number of new
T2 lesions
NCT01440062 Add-on to IFN β1b 250
μg every other day
Secondary: annualised relapse rate,
occurrence of disability progression,
proportion of patients without
disease activity, conversion rate into
definite MS, cumulative number of
T1 gadolinium-enhancing lesion,
number and volume of new T1
hypointense lesions, number and
volume of new T2 hyperintense
lesions, changes in brain
parenchymal volume, changes in
magnet resonance spectroscopy,
changes in retinal structure as
determined by optical coherence
tomography, changes in cognitive
function and fatigue, change in
health-related quality of life
Supplementation of VigantOLW
oil versus placebo as add-on in
patients with relapsing remitting
multiple sclerosis receiving
RebifW treatment (SOLAR study)
Merck-Serono GmbH February 2011/ March
2014
Cholecalciferol 14,000 IU/
day or placebo for 96
weeks
Randomised double
blind placebo-
controlled multicenter
phase II trial
348 patients with
RRMS
Primary: mean number of active
lesions at week, proportion of
relapse-free subjects
NCT01285401 Add-on to IFN β1a 44 μg
3×/week
Secondary: annualised relapse rate,
proportion of subjects free from any
EDSS progression, proportion of
subjects free from disease activity,
change in cognitive function,
cumulative number of T1 gadolinium
enhancing lesion, proportion of
subjects free from new T1
hypointense lesions, change from
baseline in the total volume of T2
lesions, percent brain volume
change with respect to baseline
A multicentre, randomised,
double-blind, placebo-controlled
study of the efficacy of
supplementary treatment with
cholecalciferol in patients with
relapsing multiple sclerosis
treated with subcutaneous IFN
Beta-1a 44 μg 3 times weekly
Merck KGaA January 2010/July
2014
Cholecalciferol 2×
100,000 IU/month or
placebo for 96 weeks
Randomised double
blind placebo-
controlled multicenter
phase II trial
250 patients with
RRMS
Primary: reduction of relapse rate
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Table 2 Ongoing clinical trials on vitamin D in multiple sclerosis (registered at www.clinicaltrials.gov by January 2013) (Continued)
NCT01198132 Add-on to IFN β1a 44 μg
3×/week
Secondary: number of relapse-free
subjects, cumulative probability of
progression of disability, number of
new or extended lesions in T1- and
T2-weighted MRI, changes in lesion
load (T2), number of new lesions (T1
gadolinium activity and black holes),
measurement and evaluation of
cognitive ability, change in quality of
life, safety of the treatment
A pilot study to assess the
relative safety and immunology
effects of low dose versus high
dose cholecalciferol
supplementation in patients with
multiple sclerosis
Johns Hopkins University,
Baltimore, USA
March 2010/
December 2011
Cholecalciferol 10,000 IU/
day (high dose) or
cholecalciferol 400 IU/day
(low dose) for 6 months
Randomised double
blind controlled
multicenter phase II
trial
40 MS patients
with or without
immunomodulatory treatment and
serum 25(OH)VD levels between 20–
50 ng/ml
Primary: safety of high-dose
cholecalciferol, effects of
cholecalciferol supplementation
on serum immune markers
NCT01024777 Secondary: clinical effects of
cholecalciferol supplementation
A randomised controlled trial of
vitamin D supplementation in
multiple sclerosis
Johns Hopkins University,
Baltimore, USA
March 2012/
December 2014
Cholecalciferol 5,000 IU/
day (high dose) or
cholecalciferol 600 IU/day
(low dose) for 24 months
Randomised double
blind controlled
multicenter phase III
trial
172 RRMS patients
with 25(OH)D-
serum levels ≥ 15
ng/ml
Primary: proportion of subjects that
experience a relapse
NCT01490502 Add-on to glatiramer
acetate 20 mg/day
Secondary: annualised relapse rate,
occurrence of sustained disability
progression, number of new T2
lesions, changes in brain
parenchymal volume and cortical
thickness, change in low-contrast
visual acuity, change in health-
related quality of life, development
of hypercalcemia/related adverse
effects
Pharmacodynamic and
immunologic effects of vitamin D
supplementation in patients with
multiple sclerosis and healthy
controls
Johns Hopkins University,
Baltimore, USA
November 2010/June
2013
Cholecalciferol 5,000 IU/
day for 90 days
Non-randomised,
open label single
group assignment
multicenter phase 1
trial
60 patients with
RRMS or healthy
individuals
Primary: change in mean serum level
of 25(OH)VD
NCT01667796 Secondary: cytokine levels and
percentages of T and B cells, gene
expression microarray
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Table 2 Ongoing clinical trials on vitamin D in multiple sclerosis (registered at www.clinicaltrials.gov by January 2013) (Continued)
Role of vitamin D on the relapse
rate of multiple sclerosis
AlJohara M AlQuaiz, M.D.,
King Saud University,
Saudi Arabia
January 2013/October
2014
Cholecalciferol 50,000 IU/
week or placebo for 12
months
Randomised double
blind controlled
single centre phase II
trial
200 patients with
RRMS
Primary: relapse rate
NCT01753375 Secondary: improvement in the EDSS
score
Dose-related effects of vitamin
D3 on immune responses in
patients with clinically isolated
syndrome and healthy control
participants. An exploratory
double blind placebo
randomised controlled study
University College Dublin,
Ireland
November 2012/May
2014
Cholecalciferol 5,000 IU/
day or 10,000 IU/day or
placebo for 24 weeks
Randomised double
blind placebo-
controlled phase II
trial
45 patients with
CIS without any
immunomodulatory treatment and
39 healthy individuals
Primary: change in the frequency
of CD4 T cell subsets and
cytokine responses of periphery
blood mononuclear cells
NCT01728922 Secondary: relapse occurrence,
percentage of CIS patients in each
treatment arm free from any
evidence of disease activity, number
of new T2 and gadolinium-
enhancing lesions
Abbreviations: CIS clinically isolated syndrome, EDSS expanded disability status scale, IFN interferon, IU international units; RRMS relapsing remitting multiple sclerosis.
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observed with respect to relapse rate and disability [118].
Two recently published studies from Finland and Norway,
both applying 20,000 IU/week in a randomised, double
blind and placebo-controlled design (evidence level Ib),
yielded partly contradictory results with respect to clinical
and MRI parameters. In the Finish study, mean 25(OH)
VD serum levels in patients receiving VD over 1 year in
addition to IFN-β increased to 110 nmol/l, and patients in
the verum group showed significantly fewer gadolinium-
enhancing lesions and a tendency to reduced disability
accumulation and improved ambulation parameters. The
annualised relapse rate was not different in both arms
[119]. In an active subgroup of this study, an additional
beneficial effect of VD on new/enlarging T2 hyperintense
brain lesions was observed [120]. In the 96-weekNorwegian
trial, no significant differences were observed in annualised
relapse rate, EDSS,MSFC, grip strength, or fatigue although
the median 25(OH)VD serum concentration in the verum
group raised to 121 nmol/l [121].
In summary, due to their ambiguous results, the so-far
published interventional trials do not answer the question
whether VD would be a treatment option in MS. The rea-
sons for these heterogeneous results remain unclear.
Given the substantial increase in serum concentration to
greater 100 nmol/l in the two most recent trials [119,121],
insufficient dosing is probably not a likely explanation.
Further, well-designed interventional high-dose trials, which
are at least partly better powered, are currently underway
(Table 2) [122,123] and will hopefully contribute to eluci-
date the efficacy aspects.
With respect to safety, more clinical data already exist.
Generally, (iatrogenic) VD excess can result in life-
threatening hypercalcaemia and has been occasionally
reported on the basis of single cases [124]. However,
unlike supplementation with high dose calcitriol, which
indeed seems to bear a significant risk of symptomatic
hypercalcaemia [125], treatment of MS patients with even
very high doses of cholecalciferol or ergocalciferol was re-
peatedly demonstrated to be safe [113,114,116,119,121].
While a Cochrane report published in 2010 concludes that
available data are not yet sufficient to draw the right con-
clusions regarding safety of VD supplementation [126],
another recent meta-analysis suggests that daily doses of
10,000 IE cholecalciferol can be considered safe [127].
Conclusions
In this review article, which follows the recommenda-
tions of the “EPMA White Paper” [128], we summarise
and discuss available data on the role of VD for the
development and disease course of MS. Many lines of
evidence, in particular epidemiologic data, preclinical
investigations, animal studies, and association studies on
VD status and disease activity, suggest that higher serumconcentrations of VD are beneficial in terms of the risk to
develop MS as well as the further course of the disease in
already-established MS. Moreover, VD supplementation is
safe, cheap, and convenient to perform. Therefore, it is in-
triguing to hypothesise that boosting the VD serum levels
would be an option to both prevent and treat MS. Despite
the inherent methodological drawbacks of epidemiologic
studies, existing data on the preventive capacity of higher
VD levels are quite compelling. Final proof of this hypoth-
esis would be reached by large-scale prospective epidemio-
logical studies which will probably not be available in the
near future, for obvious reasons. With respect to the
therapeutic efficacy, an association between higher VD
serum concentrations and a favourable disease course has
been conclusively shown. Unfortunately, the so-far per-
formed interventional trials, though not negotiating this
hypothesis, also do not unambiguously support the idea
that raising patients' VD levels would be favourably in
terms of disease outcome. Hopefully, ongoing (Table 2)
and future trials will shed more light on this aspect.
But, how are we going to deal with this issue in the
meantime? From a pragmatical point of view and consid-
ering available data on efficacy, safety, tolerability, and last
but not least costs, it seems to be reasonable to regularly
control 25(OH)VD levels in MS patients, especially during
winter months. In patients with inadequate VD, levels
should be raised to at least 30–40 ng/ml (75–100 mmol/l),
either by appropriate sun exposure and/or adequate VD
supplementation. As a rule of thumb, supplementary 1 μg
(40 IU) cholecalciferol will increase 25(OH)VD levels by 1
ng/ml (2.5 nmol/l).
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